Home |About Us |Resources|Advertisement

 cancer chemotherapy                                                             


Chemotherapy Drug Helps Metastatic Prostate Cancer Live Way Longer


Hearing from a health care provider "the cancer has spread, I am sorry" is really painful for a cancer patient to hear. But there is good news for patients whose prostate cancer has spread beyond the prostate gland. Patients who struggle with metastatic prostate cancer may increase their survival by almost a year and a half by supplementing a chemotherapeutic drug in the beginning of the hormone therapy.

According to a recent study, patients with metastatic prostate cancer can live up to 18 months longer simply by introducing Docetaxel at the beginning of their hormone therapy. Docetaxel may be unfamiliar to most patients, but it is a chemotherapy drug commonly used to fight metastatic prostate cancer that has spread beyond its original location. 

The doctor Sanjay Wine, medical oncologist at Austin Cancer Centers, said docetaxel has always brought good results. "The traditional belief has been to complete all the hormone therapy," said Vin. "Then once they progress or fail hormone therapy to use this chemotherapy." Now we know from a recent study this year, when the drug chemotherapy Docetaxel is given at about the same time as hormone therapy, the overall survival in men with a high volume of metastatic prostate cancer increased from 32 months to 49 months.

Most often the difference in survival is around three months or less. In this case, the difference is more than 17 months, which is very considerable for a solid tumor. This survival length may even increase in some patients who adopt a healthy lifestyle and an appropriate diet against cancer. Consult your nutritionist for a proper diet against cancer of the prostate.

There are many people who have been diagnosed with metastatic prostate cancer years from now that are living a normal life until now. Their cancer was confined to the prostate without impairing or considerably endangering their life. The results of the study are encouraging. In Fact, one of the survivors, Mr. Fifty-eight-year-old Karl Hancock of Spicewood Said ""It gives me a lot more hope than a lot of stories I've read about other people who didn't have this option,"

The main author of the study, Christopher Sweeney, MBBS, said this is the first study to identify a therapeutic strategy to prolong survival so long. The advantage is significant and encouraging in the progress in chemotherapy. Who knows if other studies are not going to reveal another plan to prolong life of metastatic prostate cancer for up to 10 years?